TCR Bispecific

Deals and Financing

T Therapeutics Closes Series B for TCR Bispecific Programs

T-Therapeutics announced a $133 million Series B on November 5 to take TCR-CD3 bispecific programs in oncology and autoimmune disease toward clinical proof of concept. The round finances development; neither program has disclosed human…

admin
November 5, 2026

Leadership Tracker

T Therapeutics Appoints Kirsty Crame Chief Development Officer

T-Therapeutics announced on November 5 that Kirsty Crame joined as chief development officer to oversee translational and clinical development alongside its Series B close. No predecessor or separate effective date was identified; the reason…

admin
November 5, 2026

T Therapeutics Closes Series B for TCR Bispecific Programs

T Therapeutics Appoints Kirsty Crame Chief Development Officer

Saturday Rounds